ANI Pharmaceuticals Completes $210m Novitium Acquisition
Acquisition Expected To Bolster R&D, Generics Scale And CDMO Business
ANI Pharmaceuticals has completed its acquisition of niche generics specialist Novitium Pharma, securing access to a pipeline of generics and 505(b)(2) candidates that has expanded further since the deal was announced earlier in the year.
You may also be interested in...
ANI Pharmaceuticals has recorded its highest-ever quarterly revenue of $73.9m during Q2, following the launch of its cortrophin gel and a substantial growth in generics revenue.
Teva has appointed a new general manager in Canada following the departure of Christine Poulin to Covis Pharma. At the same time, Amneal’s associate general counsel, Meredith Cook, has taken up a role at ANI Pharmaceuticals, while Alvotech has appointed several new directors to its board as part of its transition to being a publicly-listed company.
ANI Pharmaceuticals has announced the closure of its Oakville, Ontario manufacturing plant, a move which is expected to save the firm $7m to $8m.